Gene/Cell Therapies: US FDA Clarifies INTERACT, Pre-IND Meeting Timing In FAQ Guidance

 
• By Sue Sutter
  
Question marks on blocks
A new FDA guidance answers frequently asked questions about gene and cell therapy product development. (Shutterstock)

More from Cell & Gene Therapies

More from Pathways & Standards